---
aliases:
  - HDAC inhibitors
  - HDACis
  - HDAC
---
Histone deacetylase inhibitors (HDAC inhibitors, or HDACis) are a class of [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] that target histone deacetylases, enzymes involved in the modification of chromatin structure and regulation of [[gene]] expression. By inhibiting these enzymes, HDAC inhibitors can alter the expression of genes that control cell growth, differentiation, and apoptosis, making them useful in the treatment of certain cancers and other diseases.

### Key Points About Histone Deacetylase (HDAC) and HDAC Inhibitors:

1. **Role of Histone Deacetylases (HDACs)**:
   - HDACs are enzymes that remove acetyl groups from histones, the proteins around which DNA is wrapped. This deacetylation causes the chromatin (DNA-protein complex) to become more condensed, leading to reduced [[gene]] expression because the DNA becomes less accessible to the transcriptional machinery.
   - Conversely, histone acetyltransferases (HATs) add acetyl groups to histones, loosening the chromatin structure and promoting [[gene]] expression.

2. **Mechanism of HDAC Inhibitors**:
   - HDAC inhibitors block the activity of HDACs, leading to an accumulation of acetylated histones and a more open chromatin structure. This change in chromatin structure can activate the expression of genes involved in cell cycle arrest, differentiation, and apoptosis (programmed cell death).
   - By promoting these processes, HDAC inhibitors can suppress the growth of cancer cells and induce their death.

3. **Types of HDAC Inhibitors**:
   - HDAC inhibitors can be classified based on their chemical structure and specificity for different HDAC isoforms. Some common types include:
     - **Hydroxamic acids**: These include [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] like **[[vorinostat]] (Zolinza)** and **[[panobinostat]] (Farydak)**.
     - **Cyclic peptides**: Such as **[[romidepsin]] (Istodax)**.
     - **Benzamides**: For example, **entinostat**.
     - **Aliphatic acids**: Such as **valproic acid**, which is also used as an anticonvulsant.

4. **Clinical Uses**:
   - HDAC inhibitors are primarily used in the treatment of certain hematologic cancers, such as:
     - **Cutaneous T-cell [[Lymphoma]] (CTCL)**: [[vorinostat]] and [[romidepsin]] are approved for treating CTCL, a type of non-Hodgkin [[Lymphoma]] that affects the skin.
     - **Peripheral T-cell [[Lymphoma]] (PTCL)**: [[romidepsin]] is also approved for PTCL.
     - **Multiple [[myeloma]]**: [[panobinostat]], in combination with other therapies, is used to treat multiple [[myeloma]], a cancer of plasma cells.
   - Research is ongoing to explore the use of HDAC inhibitors in other cancers, including solid tumors, and in non-cancerous conditions such as neurodegenerative diseases, inflammatory diseases, and psychiatric disorders.

5. **Side Effects**:
   - Common side effects of HDAC inhibitors include fatigue, nausea, vomiting, diarrhea, [[thrombocytopenia]] (low platelet count), [[neutropenia]] (low white [[Blood]] cell count), and anemia.
   - More serious side effects can include cardiac toxicity (such as QT prolongation), infections due to immune suppression, and gastrointestinal bleeding.
   - Because HDAC inhibitors affect a broad range of genes, they can have widespread effects on normal cells, leading to toxicity and limiting their use.

6. **Mechanisms of Resistance**:
   - As with other cancer therapies, resistance to HDAC inhibitors can develop. Mechanisms of resistance may include mutations in HDACs or other components of the chromatin-modifying machinery, activation of alternative signaling pathways, or changes in drug metabolism.
   - Overcoming resistance is a key area of research, with strategies including combination therapies (e.g., combining HDAC inhibitors with other targeted therapies or chemotherapies) and the development of next-generation HDAC inhibitors with improved specificity and reduced toxicity.

7. **Research and Future Directions**:
   - Research continues into the broader therapeutic potential of HDAC inhibitors, including their use in combination with other cancer treatments such as immunotherapy, and their application in other diseases where [[gene]] expression modulation may be beneficial.
   - Understanding the specific roles of different HDAC isoforms in various diseases is crucial for the development of more selective HDAC inhibitors that minimize side effects.

In summary, histone deacetylase inhibitors are an important class of [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] used in the treatment of certain cancers by altering [[gene]] expression through chromatin modification. While effective, these [[Boxes/Temple College Nursing Program/LVN Program/Fall 24/Pharmacology/Drugs/Drugs|Drugs]] come with significant side effects, and ongoing research aims to refine their use and expand their application to other diseases.